4-Hydroxy-N-propyl-N-isopropyltryptamine (4-HO-PiPT, Piprocin) is a substituted tryptamine derivative which is claimed to have psychedelic effects. It acts as a 5-HT2A receptor agonist, with an EC50 of 13.8 nM and an efficacy of 104.8% (vs 5-HT),[1] and has been sold as a designer drug, first being identified in 2021 in British Columbia, Canada.[2]

See also

References

  1. ^ Banister S, Jorgensen W, Jinlong T. Compounds. Patent WO 2023/115167
  2. ^ Knill A, Tobias S, Matthews J, Ti L (June 2022). A Report on British Columbia's Unregulated Drug Supply. Drug checking trends across British Columbia, January to December 2021 (PDF). British Columbia Centre on Substance Use (Report).